Taken together, our results indicate that MEPT is a potent autophagy agonist in oral cancer cells with antitumor therapeutic potential that acts through the mitogen-activated protein kinase (MAPK) pathway. The gene discussed is WNK2; the disease is lip and oral cavity carcinoma.